ImClone Systems, the maker of the anticancer drug Erbitux, said a $4.5 billion takeover bid by Bristol-Myers Squibb “substantially undervalues” the company.
05
4:24
August '08
ImClone Systems, the maker of the anticancer drug Erbitux, said a $4.5 billion takeover bid by Bristol-Myers Squibb “substantially undervalues” the company.